MiR-1 inhibits prostate cancer PC3 cells proliferation through the Akt/mTOR signaling pathway by binding to c-Met.


Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 05 08 2018
revised: 11 10 2018
accepted: 18 10 2018
entrez: 16 12 2018
pubmed: 16 12 2018
medline: 29 3 2019
Statut: ppublish

Résumé

Prostate cancer (PC) is known as the most common cancer and is ranked second in cancer-related deaths in males. Accumulating evidence implicates microRNAs (miRNAs) may play key roles in tumorigenesis. We investigated the effects of microRNA-1 (miR-1) on the viability and proliferation of prostate cancer cells and the underlying mechanism. We first detected the miR-1 expression level in the PC cells by quantitative real-time PCR (qRT-PCR). The relation between the level of miR-1 and c-Met was investigated via luciferase reporter assay. Cell viability and proliferation were analyzed via MTT assay and flow cytometry in PC cells. Western blot was used for examining the related signaling pathway. MiR-1 expression was decreased and c-Met expression was increased in PC cells. Subsequently, we found that overexpression of miR-1 could inhibit viability and proliferation of PC cells functionally. Furthermore, the dual luciferase reporter assay results indicated that the c-Met is the target gene of miR-1. Western blot results indicated that this inhibition on the viability and proliferation of PC cells was via regulation of c-Met/AKT/mTOR signaling pathway. In conclusion, this study provides novel insight into the role of miR-1 in PC, and the results demonstrated that miR-1 could inhibit viability and proliferation of PC cells by targeting the c-Met/Akt/mTOR signaling pathway. MiR-1 might be a potential candidate for application in the treatment of PC.

Identifiants

pubmed: 30551391
pii: S0753-3322(18)35436-2
doi: 10.1016/j.biopha.2018.10.098
pii:
doi:

Substances chimiques

MIRN1 microRNA, human 0
MicroRNAs 0
MTOR protein, human EC 2.7.1.1
MET protein, human EC 2.7.10.1
Proto-Oncogene Proteins c-met EC 2.7.10.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1
TOR Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1406-1410

Informations de copyright

Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Auteurs

Song Gao (S)

The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, No. 39 Huaxiang Road, Tiexi District, Shenyang, 110022, China.

Zhiying Zhao (Z)

School of Computer Science and Engineering, Northeastern University, No. 3-11, Wenhua Road, Heping District, Shenyang, 110004, China.

Rong Wu (R)

The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, No. 39 Huaxiang Road, Tiexi District, Shenyang, 110022, China.

Lina Wu (L)

The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, No. 39 Huaxiang Road, Tiexi District, Shenyang, 110022, China.

Xin Tian (X)

The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, No. 39 Huaxiang Road, Tiexi District, Shenyang, 110022, China.

Zhenyong Zhang (Z)

The Second Department of Clinical Oncology, Shengjing Hospital, China Medical University, No. 39 Huaxiang Road, Tiexi District, Shenyang, 110022, China. Electronic address: medzz66@sina.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH